Seven cases of Saccharomyces fungaemia related to use of probiotics

Mycoses

Volumn 60, Issue 6, 2017, Pages 375-380

  Roy, Ujjwayini ^a   Jessani, Laxman G ^b   Rudramurthy, Shivaprakash M ^c   Gopalakrishnan, Ram ^b   Dutta, Soma ^a   Chakravarty, Chandrashish ^a   Jillwin, Joseph ^c   Chakrabarti, Arunaloke ^c  

^a Apollo Gleneagles Hospital   (India)

^b APOLLO HOSPITALS   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

fungaemia; management; outcome; probiotics; Saccharomyces

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PROBIOTIC AGENT; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; RIBOSOME RNA; RNA, RIBOSOMAL, 26S;

ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; FEMALE; FUNGEMIA; HUMAN; INDIA; INTENSIVE CARE UNIT; MALE; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE; ANTIFUNGAL RESISTANCE; CRITICAL ILLNESS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIGENE FAMILY;

ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGEMIA; HUMANS; INDIA; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MULTIGENE FAMILY; PROBIOTICS; RNA, RIBOSOMAL; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; VORICONAZOLE;

EID: 85011085705     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12604     Document Type: Article

References (27)

1. Ravtava S. Potential uses of probiotics in the neonates. Semin Fetal Neonatal Med. 2007;12:45–53.
2. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci. 2008;53:2524–2531.
3. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503–514.
4. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol. 2010;16:403–410.
5. Isolauri E, Rautava S, Salminen S. Probiotics in the development and treatment of allergic diseases. Gastroenterol Clin North Am. 2012;41:747–762.
6. Luedtke SA, Yang JT, Wild HE. Probiotics and necrotizing enterocolitis: finding the missing pieces of the probiotic puzzle. J Pediatr Pharmacol Ther. 2012;17:308–328.
7. Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25:1919–1929.
8. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014;13:227–239.
9. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2):S129–S134.
10. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for Clostridiumdifficile disease. JAMA. 1994;271:1913–1918.
11. Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517–523.
12. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants with Saccharomyces boulardii. Early Human Dev. 2003;74:89–96.
13. Schneider SM, Girard-Pipau F, Filippi J, et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol. 2005;11:6165–6169.
14. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeastsbased on nucleotide divergence in the 5′end of the large-subunit (26S) ribosomal DNA gene.
15. Chakrabarti A, Rudramurthy SM, Kale P, et al. Epidemiological study of a large cluster of fungaemia cases due to Kodamaea ohmeri in an Indian tertiary care centre. Clin Microbiol Infect. 2014;20:O83–O89.
16. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard third edition; CLSI document M27 A3. Wayne: Clinical and Laboratory Standards Institute, 2008.
17. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: fourth informational supplement—CLSI document M27-S4-Wayne, PA. 2012.
18. Bernardo WM, Aires FT, Carneiro RM, Sá FP, Rullo VE, Burns DA. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. J Pediatr (Rio J). 2013;89:18–24.
19. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011;200:1–645.
20. Wallace TC, Mackay D. The safety of probiotics: considerations following the 2011 US. Agency for Health Research and Quality Report. J Nutr. 2011;141:1923–1924.
21. Muñoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625–1634.
22. Piarroux R, Millon L, Bardonnet K, Vagner O, Koenig H. Are live saccharomyces yeasts harmful to patients? Lancet. 1999;353:1851–1852.
23. Lherm T, Monet C, Nougière B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002;28:797–801.
24. Salonen JH, Richardson MD, Gallacher K, et al. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae. J Hosp Infect. 2000;45:293–301.
25. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16–20.
26. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis. 2005;41:1559–1568.
27. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer. 2000;8:504–505.